Skip to content

Author

D. van Klaveren

We have 4 of 216 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Survival Outcomes in Hepatocellular Carcinoma: A Decade of Treatment in a Western Tertiary Referral Center.

BACKGROUND & AIMS Hepatocellular carcinoma (HCC) remains a challenging malignancy with various available treatments. This retrospective study provides clinical outcomes on staging, treatment, and overall survival (OS) of HCC patients. METHODS All included patients were diagnosed between 2013 and 2022. OS was assessed...

P. E. van der Meeren, L. Beuk, G. Milinovic et al. · 0 citations
Open access Oct 2026

Active surveillance versus standard surgery after neoadjuvant chemoradiotherapy for oesophageal cancer: long-term results of a cluster-randomised controlled trial (SANO).

BACKGROUND The Surgery As Needed for Oesophageal cancer (SANO)-trial demonstrated that active surveillance is non-inferior to standard surgery in terms of two-year overall survival in patients with a complete clinical response after neoadjuvant chemoradiotherapy (nCRT). Active surveillance resulted in improved quality...

S. S. G. Gangaram Panday, B. J. van der Wilk, S. Lagarde et al. · 0 citations
Open access Oct 2026

The association between fluid management and hemodynamic parameters in patients with acute brain injury.

PURPOSE Higher fluid input (FI) resulting in more positive fluid balance (FB) is associated with worse outcome in aneurysmal subarachnoid hemorrhage (aSAH) and traumatic brain injury (TBI) patients. Although venous congestion could be a possible mechanism behind these associations, hemodynamic studies elucidating these...

Saliha Ergezen, Şebnem Yıldırım, D. van Klaveren et al. · 0 citations
Open access Jul 2026

Validated 1-Year Mortality Prediction in Patients with Three-Vessel Disease Undergoing Contemporary PCI: Insights from the Multivessel TALENT trial.

In contemporary PCI for 3VD, the LCSS showed moderate discrimination for 1-year all-cause mortality while overestimating its absolute risk, although observed mortality increased across predicted-risk quintiles.

A. Oshima, N. Kanehama, D. van Klaveren et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.